Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells

Abstract

Aim: We investigated the feasibility of dynamin 2 as a potential treatment target in cervical cancer cells. Materials and Methods: We performed tissue microarray for dynamin 2 expression in 208 patients with early cervical cancer and in vitro in HeLa cells with dynamin 2 inhibitors MiTMAB, OcTMAB, Dynasore, and DD-6. Results: Tumor size greater than 2 cm or tumor invasion of more than half of the entire cervix was associated with expression of dynamin 2 compared to no expression (p=0.013, and p=0.045, respectively). All dynamin 2 inhibitors significantly reduced proliferation, increased apoptotic activity, and reduced matrix metallopeptidase 9 expression in HeLa cells. Dynasore and DD-6 reduced migration of HeLa cells on laminin 1-coated plates and DD-6 most strongly reduced migration performance on fibronectin-coated plates. Conclusion: Targeting dynamin 2 may be a promising new approach for the treatment of cervical cancer.